AAV-vectored immunoprophylaxis for the prevention and treatment of infectious diseases

AAV 载体免疫预防用于预防和治疗传染病

• 批准号: 478670
• 负责人: Wootton Sarah
• 金额: $ 55.45万
• 依托单位: Avamab Pharma Inc. (Calgary, Alberta)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2023
• 资助国家: 加拿大
• 起止时间: 2023-03-01 至 2028-03-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=478670&lang=en
• 关键词: Adeno-Associated Virus (Aav); Alternative Vaccine Platform; Anti-Drug Antibodies; Emerging Infectious Diseases; Immune Response To Aav; Immunoprophylaxis; Large Animal Models; Monoclonal Antibody; Recrudescence; Who Priority Pathogens

Adeno-associated virus (AAV)-mediated expression of pathogen specific, broadly protective monoclonal antibodies (mAb) has been demonstrated to provide protection against a variety of infectious diseases in a range of animal models and is now being tested

腺相关病毒（AAV）介导的病原体特异性、广泛保护性单克隆抗体（mAb）的表达已被证明在一系列动物模型中提供针对多种感染性疾病的保护，并且现在正在进行测试